Exchange: NASDAQ·Updated 11:55 PM EDT
APRE logo

APRE Aprea Therapeutics Inc

$0.9432
$0.0368
(3.75%)
Overnight
Prev Close $0.98
Mkt Cap$11.96M
Vol2.82M

About APRE

Aprea is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The Company is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors while minimizing the effect on normal, healthy cells. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, endometrial, colorectal and head and neck squamous cell carcinoma. The Company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications.
89

Extremely Bullish Sentiment

How do you feel about APRE?

Advertisement|Remove ads.